// App-Quantinova.ai

4047 : Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).

Researchers

Presenter

  • Daisuke Takahari

Principal Investigators

  • Hirokazu Shoji

  • Hiroki Hara

  • Taito Esaki

  • Nozomu Machida

  • Kengo Nagashima

  • Kazunori Aoki

  • Kazufumi Honda

  • Takahiro Miyamoto

  • Narikazu Boku

  • Ken Kato

Medical Centers

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  • Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan

  • Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Japan, Shizuoka, Japan

  • Department of Global Clinical Research, Graduate School of Medicine, Chiba University, Chiba, Japan

  • Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

  • Department of Biomarker for Early Detection of Cancer, National Cancer Center Research Institute, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Ramucirumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02999295

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved